Boston Scientific (NYSE:BSX) announced today that it entered into a definitive agreement to sell its BTG Specialty Pharmaceuticals business. Marlborough, Mass.-based Boston Scientific is selling BTG for $800 million in cash to Stark International Lux S.A.R.L. and SERP SAS, both affiliates of European specialty pharmaceutical group SERB, according to a news release. Get the full story…